ライフサイエンスコーパス: aprotinin

1 more effective than the reference inhibitor aprotinin.

2 1 activation by thrombin can be inhibited by aprotinin.

3 let aggregation (P<0.001) in the presence of aprotinin.

4 ed by the plasmin/serine protease antagonist aprotinin.

5 5.4 U, P<0.002) than patients not prescribed aprotinin.

6 ta by TSP, but not by the plasmin inhibitor, aprotinin.

7 ition of bovine plasminogen and inhibited by aprotinin.

8 se was completely inhibited by DesPro2-Arg15-Aprotinin.

9 Galardin and the serine protease inhibitor, aprotinin.

10 or inhibitor-1 and serine protease inhibitor aprotinin.

11 me inhibitors, and the intraoperative use of aprotinin.

12 r permeability and is effectively blocked by aprotinin.

13 ncludes bestatin, leupeptin, E64, AEBSF, and aprotinin.

14 8.0) containing increasing concentrations of aprotinin (0-300 muM).

15 ion, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and

16 on during CPB (n=17) and (2) those receiving aprotinin (2x10(6) kallikrein inhibitor units [KIU] in p

17 s with operating-room charges for the use of aprotinin (33,517 patients) or aminocaproic acid (44,682

18 The treatment group (n=7) was administered aprotinin (40,000 kallikrein inhibitor units [KIU]/kg lo

19 ction versus placebo, P<0.001) and high-dose aprotinin (53% reduction, P<0.001).

20 The rhK4 was inhibited by aprotinin (6 kDa), forming an equimolar 27 kDa complex.

21 ction versus placebo, P<0.010) and high-dose aprotinin (62% reduction, P<0.001).

22 A total of 1343 patients (13.2%) received aprotinin, 6776 patients (66.8%) received aminocaproic a

23 sulfoxide (DMSO)/Ringer's solution, 300 KIU aprotinin (a serine protease inhibitor), 0.05% or 0.10%

24 These processes were similarly sensitive to aprotinin, a potent inhibitor of serine proteases, inclu

25 Although aprotinin, a serine protease inhibitor, reduces blood lo

26 taneously treated with the plasmin inhibitor aprotinin, a significant reduction in the size of necrot

27 revealed by engineering the binding loop of aprotinin, a small protein with high affinity for DENV p

28 e protease inhibitors (camostat mesylate and aprotinin), affords protection against neutrophil elasta

29 Patients who received aprotinin alone on the day of CABG surgery had a higher

30 An optimized aprotinin-alpha2-PI1-8 concentration ensured ideal degra

31 Aprotinin, already approved for clinical use to reduce t

32 f Abeta40 with the serine protease inhibitor aprotinin also increased diffuse extracellular depositio

33 Use of aprotinin among patients undergoing CABG surgery does no

34 ts were randomized to receive intraoperative aprotinin, an inhibitor of several serine proteinases, o

35 However, the combination of aprotinin and ACE inhibitors during off-pump cardiac sur

36 cardiac surgery, the odds ratio (OR) between aprotinin and an increased risk of renal dysfunction wit

37 Both aprotinin and epsilon-aminocaproic acid decreased blood

38 These data suggest that aprotinin and epsilon-aminocaproic acid differ in their

39 Antifibrinolytic drugs such as aprotinin and epsilon-aminocaproic acid have been effect

40 This study examined the effects of aprotinin and epsilon-aminocaproic acid on plasma levels

41 Aprotinin and fresh whole blood were administered during

42 ntinue to suggest the virtual equivalence of aprotinin and lysine analogues in reducing bleeding and

43 We also show that surface coating with aprotinin and manual addition of aprotinin yield similar

44 sponse to cardiopulmonary bypass (CPB) using aprotinin and modified ultrafiltration.

45 of LIMA grafts between patients who received aprotinin and placebo, both groups were analyzed collect

46 s extend the clinical mechanism of action of aprotinin and provide the first proof of principle that

47 The association between aprotinin and serious end-organ damage indicates that co

48 than the gold-standard therapeutic inhibitor aprotinin, and is a promising candidate for development

49 nding of apoE-beta VLDL, lipoprotein lipase, aprotinin, and lactoferrin to megalin in a concentration

50 nogen and Spl in the presence of 100 micro M aprotinin, and plasminogen activation by pro-uPA alone w

51 rtic cross-clamp time, use of intraoperative aprotinin, and preoperative use of statin, we found that

52 iproteinase inhibitor, alpha2-macroglobulin, aprotinin, and soybean inhibitor, using trypsin as the i

53 clonal antibody, epsilon-amino-caproic acid, aprotinin, and the aminoterminal fragment of urokinase-t

54 duction/multidesulfurization of linaclotide, aprotinin, and wheat protein.

55 rHuEPO and aprotinin are now being used with increasing frequency t

56 hibitor, serum alpha-1 antitrypsin, or liver aprotinin, are a class of proteins that competitively bi

57 A recent highly publicized report implicated aprotinin as an independent causal factor for postoperat

58 a binary test set of proteins (lysozyme and aprotinin) at a pH not employed in the training set were

59 mixture of proteinase inhibitors, including aprotinin, BB-94, pepstatin, and E64.

60 Because the inhibitor aprotinin binds strongly with trypsin at alkaline pH, th

61 In presence of aprotinin, both free and aprotinin-bound trypsinogen wer

62 In presence of aprotinin, both free and aprotinin-bound trypsinogen were detected revealing a 1:

63 ted by plasminogen activator inhibitor-1 and aprotinin but not by tissue inhibitor of metalloproteina

64 Aprotinin but not epsilon-aminocaproic acid appears to a

65 cleaved PAR1 receptors, was preserved in the aprotinin but not the placebo group (P<0.05), and (3) su

66 oteolytic activity at the cell surface using aprotinin but was abolished when the gamma-inhibitory tr

67 was critical for the degradation process as aprotinin, but not alpha(2)-antiplasmin, prevented colla

68 e inhibitors, diisopropylfluorophosphate and aprotinin, but not by soybean or lima bean trypsin inhib

69 t been realized with the discontinued use of aprotinin, but rather increased blood product use has oc

70 mbin generation in humans to examine whether aprotinin can inhibit platelet PAR1 activation clinicall

71 pared by copolymerization of the PEG-trypsin-aprotinin complex during the gel-casting step.

72 etic mobility were observed upon raising the aprotinin concentration, allowing determination of their

73 nhibitor, hirudin, or the plasmin inhibitor, aprotinin, consistent with the interpretation that matri

74 Although aprotinin costs more than its alternatives, its costs ma

75 ts with high, medium, or low affinity toward aprotinin could be successfully discriminated.

76 han and phosphoramidon), serine proteinases (aprotinin), cysteine proteinases (leupeptin) and urokina

77 Compared head to head, high-dose aprotinin demonstrated significant reduction in total bl

78 t sensitivity and lowest detection limit for aprotinin detection.

79 t a microsensor dual-coated with both TF and aprotinin detects the hemostatic rescue in the tPA-induc

80 Aprotinin did not have an effect on NCD or levels of MBI

81 Aprotinin did not increase the likelihood of postoperati

82 in by both PA culture broths by 99%, whereas aprotinin did not significantly reduce the protease acti

83 with epsilon-aminocaproic acid and low-dose aprotinin (each with a 35% reduction versus placebo, P<0

84 benzenesulfonyl fluoride (AEBSF), but not by aprotinin, EDTA, or pepstatin.

85 We conducted a meta-analysis to compare aprotinin, epsilon-aminocaproic acid, and tranexamic aci

86 in a double-blind study to receive high-dose aprotinin, epsilon-aminocaproic acid, or saline placebo.

87 In the post-aprotinin era, with the exclusive use of lysine analogue

88 duct utilization would affected in this post-aprotinin era.

89 that the peptidic inhibitors, leupeptin and aprotinin, exhibited similar potencies in inhibiting fac

90 nexplained cardiopulmonary instability after aprotinin exposure, Type B).

91 akdown, rats were treated intravenously with aprotinin, followed by intravitreal injection of VEGF(16

92 ilon-aminocaproic acid may be preferred over aprotinin for reducing hemorrhage with cardiac surgery.

93 analyzed from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial in whic

94 nin levels were significantly greater in the aprotinin group (all P<0.05).

95 urs after CPB, but this was preserved in the aprotinin group (P<0.001).

96 activity was approximately 30% lower in the aprotinin group (P=0.007).

97 The aprotinin group demonstrated decreased myocardial tissue

98 During the operative period, the aprotinin group received a greater number of units of pl

99 stimated risk of death was 64% higher in the aprotinin group than in the aminocaproic acid group (rel

100 ed relative risk of in-hospital death in the aprotinin group was 1.78 (95% CI, 1.56 to 2.02).

101 sk for renal dysfunction was observed in the aprotinin group.

102 Patients who received aprotinin had a higher mortality rate and larger increas

103 epsilon-Aminocaproic acid and aprotinin had no effect on risks of postoperative myocar

104 d loss during liver hepatectomy, while 1 and aprotinin had no effect.

105 ges, as treatment with the plasmin inhibitor aprotinin had no effect.

106 Aprotinin has been demonstrated to prevent activation of

107 Of note is that aprotinin has been reintroduced into the Canadian market

108 Aprotinin has recently been associated with adverse outc

109 nolytics, e.g., tranexamic acid (TXA, 1) and aprotinin, has been challenging.

110 Hypersensitivity reactions to aprotinin have been reported in adult cardiac surgical p

111 study describes the incidence and impact of aprotinin hypersensitivity reactions in children undergo

112 Anti-aprotinin IgE was undetectable in 7 of 8 reactor cases t

113 We support the targeted use of aprotinin in adult cardiac surgery patients at high risk

114 ication of the proposed method for measuring aprotinin in pretreated plasma samples is also reported.

115 Similarly, use of aprotinin in the latter group was associated with a 55 p

116 cid, we support their use as alternatives to aprotinin in those at high risk for bleeding.

117 leeding or stroke, and discourage the use of aprotinin in those at high risk for renal failure.

118 nduced and early diabetic BRB breakdown with aprotinin indicates that azurocidin may be an important

119 etting of DHCA because of concerns regarding aprotinin-induced renal dysfunction.

120 Aprotinin inhibited azurocidin-induced BRB breakdown by

121 The serine protease inhibitor aprotinin inhibited this activation of MMPs by plasminog

122 ough its first loop, in the same manner that aprotinin inhibits trypsin.

123 (Although aprotinin is a serine protease inhibitor, here we use th

124 nt studies suggest that the antifibrinolytic aprotinin is associated with increased renal and vascula

125 The proposed electrochemical assay for aprotinin is examined further using trypsin, plasmin, an

126 Aprotinin is frequently used in high-risk cardiac surger

127 Although aprotinin is known to be effective in reducing postopera

128 The risk of hypersensitivity reactions to aprotinin is low in children undergoing cardiothoracic s

129 Aprotinin is used during cardiac surgery for its blood-s

130 ogen variants showed similar affinity toward aprotinin (Kd's of 3-9 muM), which were not significantl

131 ion of factor XIa activation of factor IX by aprotinin (Ki 0.89 +/- 0.52 microM) was non-competitive,

132 p-aminobenzamidine (Ki 28 +/- 2 microM) and aprotinin (Ki 1.13 +/- 0.07 microM) in a classical compe

133 lipoprotein (beta VLDL), lipoprotein lipase, aprotinin, lactoferrin, and the receptor-associated prot

134 the binding of apoE-beta VLDL, lactoferrin, aprotinin, lipoprotein lipase, and RAP to megalin is eit

135 The design was based on two aprotinin loops and aimed to leverage both key specific

136 of endogenous serine protease activity with aprotinin markedly decreased ENaC-mediated currents and

137 However, aprotinin may not ameliorate the problem of perioperativ

138 PI) domain of tick anticoagulant protein, an aprotinin mutant (6L15), amyloid beta-protein precursor,

139 traoperative variables in patients receiving aprotinin (n=325) or lysine analogues (n=456).

140 he use of epsilon-aminocaproic acid (n=9) or aprotinin (n=46) in patients undergoing cardiac surgery

141 pective review of our entire experience with aprotinin (n=865), 681 first exposures, 150 second expos

142 Therefore, we assessed the affect of aprotinin on both blood transfusion requirements and ren

143 We investigated the effect of aprotinin on renal dysfunction in cardiac surgery, consi

144 cting each patient's likelihood of receiving aprotinin on the basis of preoperative characteristics a

145 were treated simultaneously with plasmin and aprotinin or a tissue inhibitor of metalloproteinases, T

146 on insulin aggregation but was not seen for aprotinin or albumin.

147 e and dog mast cell protease (dMCP)-3, i.e., aprotinin or bis(5-amidino-2-benzimidazolyl) methane (BA

148 KD1-L17R was equally or more effective than aprotinin or tranexamic acid, which have been used as an

149 may mediate BRB breakdown in early diabetes, aprotinin or vehicle was injected intravenously each day

150 R, 0.32; 95% CI, 0.15 to 0.69) and high-dose aprotinin (OR, 0.28; 0.22 to 0.37).

151 tatistically significant only with high-dose aprotinin (OR, 0.39; 0.24 to 0.61).

152 nexamic acid), the serine protease inhibitor aprotinin, or no antibleeding agent.

153 lso were inhibited by AEBSF and not by EDTA, aprotinin, or pepstatin.

154 anner by agents that inhibited plasmin, e.g. aprotinin, or that inhibited plasminogen activation, e.g

155 te quantification of recombinantly expressed aprotinin out of its host cell protein background using

156 tenuates the purported independent affect of aprotinin (P=0.231) on ARF.

157 A cocktail containing AEBSF, aprotinin, pancreatic trypsin inhibitor, leupeptin, anti

158 Aprotinin, pepstatin A, and E-64 did not affect TSF acti

159 ot affected by TIMP-1 or protease inhibitors aprotinin, pepstatin, or leupeptin but was inhibited in

160 with physisorption of tissue factor (TF) and aprotinin permits real-time assessment of the coagulatio

161 Aprotinin preserves adherens junctions after regional is

162 activated receptor, and we hypothesized that aprotinin preserves myocardial cellular junctions and pr

163 tivity of plasmin-like serine proteases with aprotinin prevented beta1 integrin/CDCP1 complexing and

164 Immunfluorescence confirmed that aprotinin prevented loss of coronary endothelial adheren

165 ti-uPAR or anti-uPA Abs or plasmin inhibitor aprotinin prior to coculturing with healthy cardiocytes

166 No adverse sequelae were attributed to aprotinin reaction.

167 Similarly, patients given aprotinin received more cryoprecipitate in the intensive

168 In all, 1512 of the 33,517 aprotinin recipients (4.5%) and 1101 of the 44,682 amino

169 Only high-dose aprotinin reduced the rate of reexploration (relative ri

170 Aprotinin reduced tyrosine phosphorylation in myocardial

171 Furthermore, as compared with aprotinin, renal toxicity was not observed with KD1-L17R

172 these results, the serine protease inhibitor aprotinin reproduced the effects of FAEEs and prevented

173 sequences and the entropic advantage driving aprotinin's high affinity.

174 Our results have shown that aprotinin seems to be safe during on-pump cardiac surger

175 s resist antiproteases, including leupeptin, aprotinin, serpins, and alpha2-macroglobulin, suggesting

176 t transfused PRBC in the model suggests that aprotinin significantly impacts ARF (P=0.008; OR=1.5).

177 However, high-dose aprotinin significantly increased the risk of renal dysf

178 Compared with saline, aprotinin significantly reduced IL-10 (P=0.02) and peak

179 Furthermore, treatment with aprotinin significantly suppressed VEGF-induced BRB brea

180 was 1.6% (180/11,198) and was higher in the aprotinin subset (2.6%, 72/2757 versus 1.3%, 108/8441; P

181 It is found that the trypsin-aprotinin system offers the highest sensitivity and lowe

182 lysis were more frequent among recipients of aprotinin than among recipients of aminocaproic acid.

183 vity of soybean trypsin inhibitor and bovine aprotinin that they nick supercoiled, circular plasmid D

184 hese data suggest that the administration of aprotinin to patients treated with DHCA does not increas

185 fibrinogen and human thrombin that includes aprotinin to reduce fibrinolysis.

186 Addition of the protease inhibitor aprotinin to the cell culture and graft perfusion media

187 nhibition with the affinity of leupeptin and aprotinin to the factor XIa-factor IX complex only appro

188 The binding of the protease inhibitor aprotinin to trypsinogen was used as protein-protein aff

189 e of renal dysfunction in patients receiving aprotinin, tranexamic acid, or no antifibrinolytic treat

190 Aprotinin (Trasylol) is used to mitigate bleeding during

191 Procrit), by maximizing red cell counts, and aprotinin (Trasylol), by inhibiting fibrinolysis, are tw

192 Aprotinin treatment (223 deaths among 1072 patients [20.

193 Aprotinin use does not independently increase the risk o

194 ed acute renal and vascular safety concerns, aprotinin use is associated with an increased risk of lo

195 nocaproic acid or no antifibrinolytic agent, aprotinin use was also associated with a larger risk-adj

196 n between perioperative variables, including aprotinin use, and renal dysfunction was assessed by ANO

197 sk-adjusted assessment of ARF in relation to aprotinin use.

198 .06; 95% CI, 0.02 to 0.22) were lower in the aprotinin versus lysine analog group (all P<0.05).

199 Aprotinin was a commonly used pharmacological agent for

200 logistic regression (C-index, 0.72), use of aprotinin was associated with a doubling in the risk of

201 ors and undergoing off-pump cardiac surgery, aprotinin was associated with a greater than two-fold in

202 However, high-dose aprotinin was associated with a statistically significan

203 ilure seen in patients who were administered aprotinin was directly related to increased number of tr

204 e instrumental-variable analysis, the use of aprotinin was found to be associated with an excess risk

205 (99m)Tc-Aprotinin was found to be useful in detecting cardiac am

206 ither with propensity adjustment or without, aprotinin was independently predictive of 5-year mortali

207 To block azurocidin, aprotinin was injected intravenously before the intravit

208 Aprotinin was used in 24.6% (2757/11,198).

209 -fused variant of the fibrinolysis inhibitor aprotinin was used to control the hydrogel degradation r

210 As expected, leupeptin and aprotinin were competitive with respect to the tripeptid

211 caproic acid, 4-aminomethylbenzoic acid, and aprotinin were developed in the 1960s without the struct

212 Aprotinin, when compared to placebo, significantly decre

213 esisting tryptic peptidase inhibitors (e.g., aprotinin), while favoring angiotensin destruction at Ty

214 in affects the interactions of leupeptin and aprotinin with the active site.

215 rvival was worse among patients treated with aprotinin, with a main-effects hazard ratio for death of

216 oating with aprotinin and manual addition of aprotinin yield similar results in inhibiting tissue pla